Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline

On Monday, Medicus Pharma Ltd. (NASDAQ:MDCX) executive leadership outlined a strategic realignment during its third-quarter 2026 financial and business update, prioritizing precision oncology and disciplined capital allocation.

Executive Chairman and CEO Raza Bokhari stated that concentrating developmental resources on the company’s licensed cancer program while establishing an independent public listing for dermatology holdings will maximize long-term shareholder value.

Advancing Precision Oncology With Pfizer Collaboration

Medicus is channeling incremental investment directly into CD228V, a clinical-stage antibody-drug conjugate targeting relapsed and refractory melanoma.

Through a license and co-development agreement with Pfizer Inc. (NYSE:PFE), Medicus secured worldwide rights to the asset.

The construct targets CD228 utilizing an established vedotin linker-payload platform refined to optimize drug exposure, tolerability, and anti-tumor activity.

Based on predecessor clinical findings from 88 patients, the company believes CD228V can achieve an objective response rate exceeding 30% in advanced melanoma.

The agreement places Medicus among roughly 30 clinical-stage ADC developers worldwide, creating potential avenues for future global commercial partnerships and out-licensing opportunities.

Spinning Out SkinJect In $135 Million SPAC Deal

To finance non-oncology programs without diverting capital from core cancer research, Medicus signed a non-binding letter of intent to merge its wholly owned subsidiary, SkinJect, Inc., with an undisclosed special purpose acquisition company.

The proposed transaction establishes an enterprise valuation of approximately $135 million for SkinJect.

Medicus expects to retain majority economic and voting control of the resulting publicly traded entity.

The deal, targeted for completion in the first half of 2027, includes concurrent equity financing to fund the SKNJCT-005 Gorlin syndrome study and prepare a New Drug Application, requiring a projected $3 million over the next two years.

Streamlining Operations And Preserving Partner Readiness

President and Chief Financial Officer Carolyn Bonner highlighted that financing activities generated net cash of $36.2 million during the first nine months of 2026, following $42.6 million raised in equity and secured debt alongside $6.4 million in debt repayments.

Medicus anticipates substantial operating expense reductions in upcoming quarters while seeking strategic partners to advance Teverelix across urology and prostate cancer indications.

MDCX Price Action: Medicus Pharma shares were up 1.58% at $1.89 during premarket trading on Monday. The stock is trading near its 52-week low of $1.70, according to Benzinga Pro data.

Photo: Photon Photo/Shutterstock